{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T04:18:53Z","timestamp":1792815533405,"version":"4.5.0"},"reference-count":144,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2004,9,20]],"date-time":"2004-09-20T00:00:00Z","timestamp":1095638400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Human Psychopharmacology"],"published-print":{"date-parts":[[2004,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Methadone is a synthetic opioid, used both as an analgesic in severe pain relief and now mainly in the treatment of opiate dependence. Such use of the drug has increased as its advantages have become widely recognized. There are undesirable outcomes from its greater use, including a substantial market in diverted methadone and a high number of deaths where the drug has been implicated. It is important to understand how and why methadone causes death so that such fatalities can be minimized, and to disseminate such information. This paper presents an overview of the chief effects of methadone on the human body, considering its metabolism, drug interactions and tolerance. The principal mechanisms by which methadone causes death are discussed: respiratory depression, aspiration of vomit, pulmonary oedema, bronchopneumonia, cardiac problems and renal failure. Many such deaths are preventable, if drug interactions and polydrug use are avoided, its longer period of metabolism and individuals' tolerance levels are considered. It is hoped that this paper will (a) help guide health professionals in their management and treatment of patients participating in methadone treatment programmes, and (b) provide some basic information for those dealing with individuals who have consumed methadone. Copyright \u00a9 2004 John Wiley &amp; Sons, Ltd.<\/jats:p>","DOI":"10.1002\/hup.630","type":"journal-article","created":{"date-parts":[[2004,9,20]],"date-time":"2004-09-20T11:01:32Z","timestamp":1095678092000},"page":"565-576","source":"Crossref","is-referenced-by-count":115,"title":["The effects of methadone and its role in fatalities"],"prefix":"10.1002","volume":"19","author":[{"given":"John M.","family":"Corkery","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Schifano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Hamid","family":"Ghodse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adenekan","family":"Oyefeso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2004,9,20]]},"reference":[{"key":"e_1_2_1_2_1","first-page":"444","article-title":"Causes and rates of death among methadone maintenance patients before and after the onset of the HIV\/AIDS epidemic","volume":"67","author":"Appel PW","year":"2000","journal-title":"Mt Sinai J Med"},{"key":"e_1_2_1_3_1","doi-asserted-by":"crossref","first-page":"489","DOI":"10.3109\/10826087009057014","article-title":"Methadone related deaths in New York City","volume":"5","author":"Baden MM","year":"1970","journal-title":"Int J Addict"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.2307\/2137033"},{"key":"e_1_2_1_5_1","unstructured":"BellisMA MorleoM HughesS et al.2004.United Kingdom Drug Situation. Annual Report to the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) 2002. The Centre for Public Health Liverpool John Moores University: Liverpool and Department of Health London."},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(77)92756-8"},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199402000-00006"},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1201\/b14312-18"},{"key":"e_1_2_1_9_1","unstructured":"Biodone.1999.Biodone. Information for health professionals datasheet. 29 October 1999.http:\/\/www.medsafe.govt.nz\/Profs\/Datashet\/b\/mBiodoneoralsoln.htmAccessed 7 March 2004."},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1177\/096032718500400109"},{"key":"e_1_2_1_11_1","first-page":"141","volume-title":"Principles of Addiction Medicine","author":"Borg L","year":"2003"},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2004.00693.x"},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.2002.00179.x"},{"key":"e_1_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.313.7052.264"},{"key":"e_1_2_1_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/09595239800187551"},{"key":"e_1_2_1_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.1993.tb02769.x"},{"key":"e_1_2_1_17_1","doi-asserted-by":"publisher","DOI":"10.3109\/10826089609045806"},{"key":"e_1_2_1_18_1","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.1999.tb127675.x"},{"key":"e_1_2_1_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-842X.2002.tb00185.x"},{"key":"e_1_2_1_20_1","first-page":"29","volume-title":"Population Trends","author":"Christophersen O","year":"1998"},{"key":"e_1_2_1_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(98)90089-3"},{"key":"e_1_2_1_22_1","doi-asserted-by":"crossref","unstructured":"CoidJ CarvellA KittlerZ HealeyA HendersonJ.2000.Opiates Criminal Behaviour and Methadone Treatment. Home Office RDS website:http:\/\/www.homeoffice.gov.uk\/rds\/pdfs\/crimebehav.pdfAccessed 08\/11\/03.","DOI":"10.1037\/e665482007-001"},{"key":"e_1_2_1_23_1","unstructured":"CorkeryJM.2002.Drug Seizure and Offender Statistics United Kingdom 2000. Home Office Statistical Bulletin 4\/02. Home Office Research Development and Statistics Directorate: London."},{"key":"e_1_2_1_24_1","volume-title":"Seizures of Drugs in the UK 2001","author":"Corkery JM","year":"2003"},{"key":"e_1_2_1_25_1","unstructured":"CPO.2001.Methadone Maintenance Guidelines. The College of Physicians of Ontario: Toronto. Available at:http:\/\/www.cpso.on.ca\/Publications\/methadone%20guide.pdf"},{"key":"e_1_2_1_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19931001)72:7<2266::AID-CNCR2820720734>3.0.CO;2-P"},{"key":"e_1_2_1_27_1","unstructured":"CSAT.2004a.Methadone\u2010Associated Mortality: Background Briefing Report. CSAT Publication. Center for Substance Abuse Treatment Substance Abuse and Mental Health Services Administration: Rockville MD.http:\/\/dpt.samhsa.gov\/reports\/methadone_mortality_briefing.docAccessed 27\/07\/04."},{"key":"e_1_2_1_28_1","unstructured":"CSAT.2004b.Methadone\u2010Associated Mortality: Report of a National Assessment May 8\u20139 2003. SAMHSA Publication No. 04\u20133904. Center for Substance Abuse Treatment Substance Abuse and Mental Health Services Administration: Rockville MD.http:\/\/www.methadone.net\/Documents\/Methadone_Associated_Mortality.htmAccessed 27\/07\/04."},{"key":"e_1_2_1_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/22.2.273"},{"key":"e_1_2_1_30_1","doi-asserted-by":"publisher","DOI":"10.1300\/J126v02n03_07"},{"key":"e_1_2_1_31_1","unstructured":"DH.1999.Drug Misuse and Dependence\u2014Guidelines in Clinical Management[Orange Guidelines]. Department of Health Scottish Office Department of Health Welsh Office Department of Health and Social Security Northern Ireland. HMSO: London. 15 March 1999. Available at:http:\/\/www.dh.gov.uk\/assetRoot\/04\/07\/81\/98\/04078198.pdf"},{"key":"e_1_2_1_32_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.70.1.10"},{"key":"e_1_2_1_33_1","unstructured":"DorseyJS.2003.Serum methadone levels and optimal dosing in methadone maintained patients. Poster presented at: American Association for the Treatment of Opioid Dependence Conference; April 13\u201316 2003. Washington DC. Poster P9 quoted in CSAT (2004a: 17)."},{"key":"e_1_2_1_34_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200038010-00003"},{"key":"e_1_2_1_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000433-199212000-00017"},{"key":"e_1_2_1_36_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199704000-00010"},{"key":"e_1_2_1_37_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200104000-00016"},{"key":"e_1_2_1_38_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200241140-00003"},{"key":"e_1_2_1_39_1","first-page":"19","article-title":"Pharmacokinetics and pharmacogenetics of methadone: clinical relevance","volume":"1","author":"Eap CB","year":"1999","journal-title":"Heroin Add Rel Clin Probl"},{"key":"e_1_2_1_40_1","volume-title":"D\u00e9c\u00e8s par Surdosage en M\u00e9thadone","author":"Eliez CA","year":"1997"},{"key":"e_1_2_1_41_1","unstructured":"European Medicines Evaluation Agency.2001.EMEA public statement on the recommendation to suspend marketing authorisation for orlaam (Levacetylmethadol) in the European Union. London 19 April 2000.http:\/\/www.emea.eu.int\/pdfs\/human\/press\/pus\/877601en.pdfAccessed 08\/11\/03."},{"key":"e_1_2_1_42_1","unstructured":"EMCDDA.2000.Reviewing Current Practice in Drug\u2010substitution Treatment in the European Union. Insights No 3. European Monitoring Centre for Drugs and Drug Addiction. Office for the Official Publications of the European Communities: Luxembourg."},{"key":"e_1_2_1_43_1","unstructured":"EMCDDA.2003.Annual Report 2003: The State of the Drugs Problem in The European Union and Norway. European Monitoring Centre for Drugs and Drug Addiction. Office for the Official Publications of the European Communities: Luxembourg."},{"key":"e_1_2_1_44_1","doi-asserted-by":"publisher","DOI":"10.1080\/146598901300271095"},{"key":"e_1_2_1_45_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197601222940424"},{"key":"e_1_2_1_46_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1999.00921.x"},{"key":"e_1_2_1_47_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.2000.95339310.x"},{"key":"e_1_2_1_48_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.1995.90571112.x"},{"key":"e_1_2_1_49_1","first-page":"153","article-title":"Aspects pharmacologiques des programmes de substitution pour les toxicomanes aux opiac\u00e9s [Pharmacological aspects of substitution programmes for opiate addiction]","volume":"33","author":"Furet Y","year":"1999","journal-title":"Revue M\u00e9d Tours"},{"key":"e_1_2_1_50_1","doi-asserted-by":"publisher","DOI":"10.1520\/JFS2002424"},{"key":"e_1_2_1_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.1970.tb01141.x"},{"key":"e_1_2_1_52_1","doi-asserted-by":"publisher","DOI":"10.1002\/chir.10303"},{"key":"e_1_2_1_53_1","first-page":"67","article-title":"Management of opioid abuse","volume":"40","author":"Ghodse H","year":"2000","journal-title":"Prescr J"},{"key":"e_1_2_1_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/0022-3999(87)90096-1"},{"key":"e_1_2_1_55_1","unstructured":"GhodseH OyefesoA HuntM et al.2000.Drug\u2010related Deaths as Reported by Coroners in England & Wales: Annual Review 1999 and np\u2010SAD Surveillance Report No. 5. Centre for Addiction Studies St George's Hospital Medical School: London."},{"key":"e_1_2_1_56_1","unstructured":"GhodseH OyefesoA WebbL PollardM CorkeryJ.2001.Drug\u2010related Deaths as Reported by Coroners in England & Wales: Annual Review 2000 and np\u2010SAD Surveillance Report No. 7. Centre for Addiction Studies St George's Hospital Medical School: London."},{"key":"e_1_2_1_57_1","unstructured":"GhodseH OyefesoA WebbL et al.2002.Drug\u2010related Deaths as Reported by Coroners in England & Wales: Annual Review 2001 and np\u2010SAD Surveillance Report No. 9. Centre for Addiction Studies St George's Hospital Medical School: London."},{"key":"e_1_2_1_58_1","unstructured":"GhodseH SchifanoF OyefesoA Jambert\u2010GrayR CobainK CorkeryJ.2003.Drug\u2010related Deaths as Reported by participating Procurators Fiscal and Coroners in England Wales Northern Ireland Scotland Isle of Man Guernsey Jersey: Annual Review 2002 and np\u2010SAD Surveillance Report No. 11. Centre for Addiction Studies St George's Hospital Medical School: London."},{"key":"e_1_2_1_59_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.323.7311.464"},{"key":"e_1_2_1_60_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2004.00752.x"},{"key":"e_1_2_1_61_1","volume-title":"NTORS after Five Years\u2014The National Treatment Outcome Research Study\u2014Changes in Substance Use, Health and Criminal Behaviour During the Five Years After Intake","author":"Gossop M","year":"2001"},{"key":"e_1_2_1_62_1","first-page":"227","article-title":"Interactions between HIV\u2010related medications and methadone: an overview","volume":"68","author":"Gourevitch MN","year":"2001","journal-title":"Mt Sinai J Med"},{"key":"e_1_2_1_63_1","first-page":"76","article-title":"Deaths related to drug poisoning: results for England and Wales, 1993 to 2000","volume":"13","author":"Griffiths C","year":"2002","journal-title":"Health Stat Q"},{"key":"e_1_2_1_64_1","first-page":"65","article-title":"Deaths related to drug poisoning: results for England and Wales, 1997 to 2001","volume":"17","author":"Griffiths C","year":"2003","journal-title":"Health Stat Q"},{"key":"e_1_2_1_65_1","first-page":"59","article-title":"Deaths related to drug poisoning: England and Wales, 1998\u20132002","volume":"21","author":"Griffiths C","year":"2004","journal-title":"Health Stat Q"},{"key":"e_1_2_1_66_1","unstructured":"HallW LynskeyM DegenhardtL.1999.Trends in Methadone\u2010related Deaths in the UK and Australia 1985\u20131995. NDARC Technical Report Number 69. National Drug and Alcohol Research Centre University of New South Wales.http:\/\/ndarc.med.unsw.edu.au\/ndarc.nsf\/c2fabb74f3f54c22ca256afc00097c53\/7da7f71e9589fed4ca256def0010b0e5\/FILE\/TR.069.PDFAccessed 7 March 2004."},{"key":"e_1_2_1_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)90427-I"},{"key":"e_1_2_1_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0379-0738(00)00282-6"},{"key":"e_1_2_1_69_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.313.7055.481"},{"key":"e_1_2_1_70_1","doi-asserted-by":"publisher","DOI":"10.1159\/000187076"},{"key":"e_1_2_1_71_1","doi-asserted-by":"publisher","DOI":"10.1021\/tx950116m"},{"key":"e_1_2_1_72_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0773.1989.tb01190.x"},{"key":"e_1_2_1_73_1","unstructured":"JacksonGWL.2002.Drug\u2010Related Deaths in Scotland in 2001. Occasional Paper No 8. General Register Office (Scotland): Edinburgh. Available at:http:\/\/www.gro\u2010scotland.gov.uk\/grosweb\/grosweb.nsf\/pages\/01ddeaths"},{"key":"e_1_2_1_74_1","unstructured":"JacksonGWL.2003.Drug\u2010Related Deaths in Scotland in 2002. General Register Office (Scotland): Edinburgh. Available at:http:\/\/www.gro\u2010scotland.gov.uk\/grosweb\/grosweb.nsf\/pages\/02drug\u2010related\u2010deaths"},{"key":"e_1_2_1_75_1","volume-title":"Drug\u2010related deaths in Scotland in 1999","author":"Jackson GWL","year":"2000"},{"key":"e_1_2_1_76_1","doi-asserted-by":"publisher","DOI":"10.1136\/ewjm.172.1.11"},{"issue":"1","key":"e_1_2_1_77_1","article-title":"Side effects and therapeutic effects","volume":"5","author":"Kramer T","year":"2003","journal-title":"Medscape Gen Med"},{"key":"e_1_2_1_78_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1978.tb16769.x"},{"key":"e_1_2_1_79_1","first-page":"193","volume-title":"Strategies for Research on the Interactions of Drugs of Abuse","author":"Kreek MJ","year":"1986"},{"key":"e_1_2_1_80_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197605132942008"},{"key":"e_1_2_1_81_1","first-page":"24","article-title":"Todesf\u00e4lle im Zusammenhang mit methadon\u2014Einahme im Kanton Genf (1987\u20131993) [Fatalities associated with methadone administration in the Geneva canton (1987\u20131993)]","volume":"196","author":"La Harpe R","year":"1995","journal-title":"Arch Kriminol"},{"key":"e_1_2_1_82_1","unstructured":"LeavittSB.2004.Methadone\u2010Drug* Interactions (*Medications illicit drugs & other substances). Addiction Treatment Forum. Special Report (peer reviewed). January 2004. Available at:http:\/\/www.atforum.com\/siteRoot\/pages\/addiction_resources\/Drug_Interactions.pdfAccessed 3 July 2004."},{"key":"e_1_2_1_83_1","unstructured":"LeavittSB KrantzMJ.2003.Cardiac Safety in MMT. Addiction Treatment Forum Special Report. Available athttp:\/\/www.atforum.com\/cardiacmmt.shtml"},{"key":"e_1_2_1_84_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000433-199506000-00002"},{"key":"e_1_2_1_85_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.141.10.1287"},{"key":"e_1_2_1_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/0376-8716(92)90058-K"},{"key":"e_1_2_1_87_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.1998.9345157.x"},{"key":"e_1_2_1_88_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.313.7070.1481a"},{"key":"e_1_2_1_89_1","unstructured":"Methadone injection.1999.Methadone injection BP. Information for health professionals datasheet. 29 October 1999.http:\/\/www.medsafe.govt.nz\/Profs\/Datashet\/m\/methadoneinj.htmAccessed 7 March 2004."},{"key":"e_1_2_1_90_1","unstructured":"Methadone syrup.1999.Methadone syrup. Information for health professionals datasheet. 29 October 1999.http:\/\/www.medsafe.govt.nz\/Profs\/Datashet\/m\/methadonesyr.htmAccessed 7 March 2004."},{"key":"e_1_2_1_91_1","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.1998.tb141444.x"},{"key":"e_1_2_1_92_1","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.53.4.277"},{"key":"e_1_2_1_93_1","volume-title":"Clarke's Isolation and Identification of Drugs","author":"Moffat AC","year":"1986"},{"key":"e_1_2_1_94_1","doi-asserted-by":"publisher","DOI":"10.1300\/J069v20n02_05"},{"key":"e_1_2_1_95_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600710110"},{"key":"e_1_2_1_96_1","doi-asserted-by":"publisher","DOI":"10.3109\/15563658308990602"},{"key":"e_1_2_1_97_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00499071"},{"key":"e_1_2_1_98_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0896-6273(00)80110-5"},{"key":"e_1_2_1_99_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.172"},{"key":"e_1_2_1_100_1","doi-asserted-by":"publisher","DOI":"10.1093\/fampra\/19.1.93"},{"key":"e_1_2_1_101_1","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/cpt1977212147","article-title":"Clinical effects and pharmacokinetics of racemic methadone and its isomers","volume":"21","author":"Olsen G","year":"1997","journal-title":"Clin Pharmacol Ther"},{"key":"e_1_2_1_102_1","first-page":"409","volume":"23","author":"Patel JA","year":"1966","journal-title":"Am J Hosp Pharm"},{"key":"e_1_2_1_102_2","volume-title":"Martindale: The Extra Pharmacopeia","author":"Wade A","year":"1997"},{"key":"e_1_2_1_103_1","first-page":"557","volume-title":"Principles of Addiction Medicine","author":"Payte JT","year":"1998"},{"key":"e_1_2_1_104_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.2000.951116475.x"},{"key":"e_1_2_1_105_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199733050-00003"},{"key":"e_1_2_1_106_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.313.7062.925"},{"key":"e_1_2_1_107_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0376-8716(01)00131-4"},{"key":"e_1_2_1_108_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.2042-7158.1971.tb09926.x"},{"key":"e_1_2_1_109_1","doi-asserted-by":"publisher","DOI":"10.1520\/JFS14088J"},{"key":"e_1_2_1_110_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1999.00974.x"},{"key":"e_1_2_1_111_1","doi-asserted-by":"publisher","DOI":"10.1152\/jappl.1985.59.6.1675"},{"key":"e_1_2_1_112_1","doi-asserted-by":"publisher","DOI":"10.1080\/1355621961000124736"},{"key":"e_1_2_1_113_1","doi-asserted-by":"publisher","DOI":"10.1080\/105504999305695"},{"key":"e_1_2_1_114_1","doi-asserted-by":"publisher","DOI":"10.1520\/JFS10071J"},{"key":"e_1_2_1_115_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.2003.00425.x"},{"key":"e_1_2_1_116_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2003.01851.x"},{"key":"e_1_2_1_117_1","unstructured":"SingletonN PendryE TaylorC FarrellM MarsdenJ.2003.Drug\u2010related Mortality Among Newly\u2010released Offenders. Home Office Online Report 16\/03. Report by Social Survey Division ONS and National Addiction Centre Institute of Psychiatry. Home Office Research Development and Statistics Directorate: London. 30 July 2003.http:\/\/www.homeoffice.gov.uk\/rds\/pdf2\/rdsolr1603.pdfAccessed 08\/11\/03."},{"key":"e_1_2_1_118_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1988.212"},{"key":"e_1_2_1_119_1","unstructured":"SquiresT RobertsonR JayJ RobinsonA BruceM.2001.National Confidential Enquiry into Methadone Related Deaths (Scotland) 2000. Clinical Resource and Audit Group 18 December 2001.http:\/\/www.show.scot.nhs.uk\/crag\/topics\/mhealth\/meth1.htmAccessed 8 November 2003."},{"key":"e_1_2_1_120_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.326.7396.959"},{"key":"e_1_2_1_121_1","first-page":"91","volume-title":"Methadone Matters: Evolving Community Methadone Treatment of Opiate Addiction","author":"Strang J","year":"2003"},{"key":"e_1_2_1_122_1","first-page":"3","volume-title":"Methadone Matters: Evolving Community Methadone Treatment of Opiate Addiction","author":"Strang J","year":"2003"},{"key":"e_1_2_1_123_1","volume-title":"Proceedings of an International Opioid Overdose Symposium held in Sydney, Australia, 14\u201315 August 1997","author":"Sunjic S","year":"1998"},{"key":"e_1_2_1_124_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-94-3-349"},{"key":"e_1_2_1_125_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.156.6.973"},{"key":"e_1_2_1_126_1","doi-asserted-by":"publisher","DOI":"10.1177\/002580240004000112"},{"key":"e_1_2_1_127_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.29.6.1278"},{"key":"e_1_2_1_128_1","unstructured":"VersterA BuningE.2000.European Methadone Guidelines. Netherlands: Methwork. June 2000. Available at:http:\/\/www.ceehm.lt\/EasyCEE\/sys\/files\/methadone%20Guidelines.doc"},{"key":"e_1_2_1_129_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.31.6.742"},{"key":"e_1_2_1_130_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.1992.tb01945.x"},{"key":"e_1_2_1_131_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)05356-2"},{"key":"e_1_2_1_132_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.2001.96811135.x"},{"key":"e_1_2_1_133_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2044.1986.tb13031.x"},{"key":"e_1_2_1_134_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.1999.9479612.x"},{"key":"e_1_2_1_135_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.309.6955.641"},{"key":"e_1_2_1_136_1","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.1997.tb122318.x"},{"key":"e_1_2_1_137_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-200208000-00001"},{"key":"e_1_2_1_138_1","unstructured":"WolffK.2003.Methadone Absorption and Metabolism. Presentation The 1st UK National Drug Treatment Conference Archive.http:\/\/www.exchangesupplies.org\/conferences\/UKNDTC\/methadoneabsorpt.htmlAccessed 7 March 2004."},{"key":"e_1_2_1_139_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.2000.951217717.x"},{"key":"e_1_2_1_140_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1997.t01-1-00591.x"},{"key":"e_1_2_1_141_1","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/37.2.205"},{"key":"e_1_2_1_142_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01225230"},{"key":"e_1_2_1_143_1","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)90269-B"},{"key":"e_1_2_1_144_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.2000.951778.x"}],"container-title":["Human Psychopharmacology: Clinical and Experimental"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhup.630","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hup.630","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T21:47:12Z","timestamp":1700171232000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hup.630"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,9,20]]},"references-count":144,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2004,12]]}},"alternative-id":["10.1002\/hup.630"],"URL":"https:\/\/doi.org\/10.1002\/hup.630","archive":["Portico"],"relation":{},"ISSN":["0885-6222","1099-1077"],"issn-type":[{"value":"0885-6222","type":"print"},{"value":"1099-1077","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,9,20]]}}}